Unicompartmental Knee Arthroplasty (UKA): Unicompartmental Knee Arthroplasty (UKA) is a less invasive treatment option compared to Total Knee Arthroplasty (TKA) for patients with primary anteromedial knee osteoarthritis.
Study summary
Unicompartmental knee arthroplasty (UKA) is the principal surgical alternative to the total knee arthroplasty (TKA) in patients with end-stage unicompartmental tibiofemoral osteoarthritis (OA) of the knee. The current comparative randomized study aims to evaluate the fixation of cemented and cementless designs of GMK-UNI unicompartmental knee prosthesis over a 5-year time period.
Eligibility
Sex
ALL
Min age
18 Years
Max age
95 Years
Healthy volunteers
No
Inclusion criteria:
* Patients with end-stage unicompartmental tibiofemoral osteoarthritis (OA) of the knee that meet the indications for use according to Medacta implants included in this study (on-label use);
* Those suffering from unilateral osteoarthritis or osteonecrosis of the medial compartment;
* Frontal deformity \< 10° (evaluated on weight-bearing long-axis x-rays);
* Flexion contracture \< 10°;
* Intact ligaments;
* Patients who are willing and able to provide written informed consent for participation in the study. Written informed consent must be obtained prior to the patient's surgery;
* Patient's age over 18 years old;
* Patient with BMI \< 40 kg/m2;
* Patients must be willing to comply with the pre and post-operative evaluation schedule.
Exclusion criteria:
* Patients with one or more medical conditions identified as a contraindication defined by the labelling on any Medacta implants used in this study;
* Any patient who cannot or will not provide informed consent for participation in the study;
* Patients who need to undergo lateral unicompartmental knee arthroplasty;
* Patients who need a revision surgery;
* Patients who need a patella-femoral joint prosthesis;
* Patients who had previously undergone high tibial osteotomy or ACL reconstruction;
* Patients with BMI ≥ 40 kg/m2;
* Patients unable to understand and take action;
* Any case not described in the inclusion criteria;
* Patients aged under 18 years;
Primary outcome measure(s)
Comparing the occurrence of radiolucency's lines — 5 yrs Compare occurrence of radiolucency's lines (both partial and complete)between the two study groups
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.